Abstract: A peelable pouch (1) comprises: a first layer (2), a second layer (3), a compartment (4) for housing the product (7), the compartment (4) being formed between the first and second layers (2, 3) by peelably sealing the first and second layers (2, 3) along a compartment sealing portion (40), which extends along the proximal portion (23, 33) and along at least a part of the two lateral portions (20, 21, 30, 31) of the first and second layers (2, 3) as well as along first (24, 34) and second branch portions (25, 35), a first tear promoting means (50) provided on the first layer (2) only, a second tear promoting means (51) provided on the second layer (3) only, and a third tear promoting means (52) provided on both the first and second layers (2,3) and extending in a direction towards the location (26) where the first and second branch portions (24, 34, 25, 35) meet.

Abstract: The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets further comprise a single film coating.

Abstract: A package comprises an outer package (2) having two members (20, 21) connected to one another via a flexible web portion (22). Each member (20, 21) comprises a base panel (200, 210) and two opposite side wall panels (201, 202, 211, 212). One of the side wall panels (201, 211) has an attachment (204, 214) portion extending towards the opposite side wall panel (202, 212). An inner package comprises blister pack members (3) comprising an edge portion (304, 314) attached to the attachment portion (204,214) of the outer package member (20, 21) such, that in a closed state the goods carried by the blister pack member are facing towards the base panel (200,210). The members (20,21) are folded towards each other via the flexible web portion (22). In an open state the outer package members (20, 21) are unfolded and the members (3) can be accessed by folding the blister pack member (30, 31) away from the opposite side (202, 212) wall panel.

Abstract: The invention relates to beneficial topical pharmaceutical compositions comprising diclofenac sodium salt in unusually low amounts. The compositions represent opaque emulsion-gels, in which diclofenac is kept fully dissolved.

Abstract: The invention relates to a solid dosage form which is rapidly disintegrating in aqueous medium. Especially, the invention relates to pharmaceutical, orally ingested solid dosage forms, which are designed to disintegrate rapidly within the mouth, and to analogous veterinary dosage forms. Moreover, the invention relates to a unique process for the manufacture of said solid dosage forms.

Abstract: Processes for the depletion of 7-ADCA in mixtures of vinyl-ACA with 7-ADCA via novel salts of vinyl-ACA or via chromatography.

Abstract: A process for the purification of cefixime via a novel tert-octylamine salt of a cefixime intermediate of formula V which may be crystalline and which may be produced in a one-pot reaction from 7-amino-3-vinyl-ceph-3-em-4-carboxylic acid.

Abstract: A process which comprises (i) acylating a compound of formula II with a compound of formula IV to obtain a compound of formula I and (ii) deformylating said compound of formula I to obtain a compound of formula III

Abstract: A compound of formula (I) wherein R2 is arylene or heterocyclene; or R and R2 together with the nitrogen atom to which they are attached form non-aromatic heterocyclene; and the other residues have various meanings, useful as pharmaceuticals, e.g. antimicrobials.

Abstract: A process for the production of a compound of formula comprising i) silylating a compound of formula then reacting a resulting with a compound of formula R′BS—X′  IVB wherein R′B is hydrogen or trialkysilyl and X′ is as defined above, in the presence of a compound of formula wherein R2, R3 and R4 independently of each another are aryl or alkyl, and R5 is alkyl, perfluorinated alkyl, or aryl; and isolating the desired product.

Abstract: A compound selected from 14—O—[(cycloalkyl-sulfanyl)acetyl]mutilins; 14—O—[(cycloalkyl-alkyl-sulfanyl)acetyl] mutilins; 14—O—[(cycloalkoxy)acetyl] mutilins; and 14—O—[(cycloalkyl-alkoxy)acetyl] mutilins and its use as a pharmaceutical.

Abstract: A novel crystal form the pharmaceutical compound olanzapine, processes for its preparation and its pharmaceutical use are disclosed.

Abstract: Azithromycin in the form of a stable monohydrate and processes for the preparation of azithromycin in the form of an, e.g. stable, monohydrate.

Abstract: Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.

Abstract: Monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection, paticularly in combination with other antibodies to activated T-cells, for example CD7 antibodies.

Abstract: Process for preparing ceftiofur having formula I: in the form of the sodium salt.

Abstract: One of the problems facing transplantation procedures today is the availability of organs suitable for transplantation. A way around the lack of organs, it to harvest organs from animals. However, immune reactions between discordant donor and recipient mammals presents a major obstacle in such transplantation procedures. The production of transgenic non-human mammals expressing a DNA sequence encoding an homologous complement restriction factor or factors of a discordant mammalian species such that the expression of the DNA sequence would prevent xenograft rejection by the host mammal's immune system would provide organs, tissues and cells for transplantation.